If these pre-clinical observations hold true in human tumours, it may be possible to improve radiotherapy response by using hypofractionated schedules in p53 WT tumours and conventional fractionation to a higher total dose in p53-mutant tumours. This evidence concerns the gene TP53 and neoplasm.